Lausanne, Switzerland – August 8, 2024.
PeriVision, an innovative spin-off from the University of Bern and the University Hospital Bern, announces that it has entered into a distribution agreement with Von Hoff, a leading ophthalmic medical device distributor in Switzerland and Liechtenstein, to commercialize the VisionOne VR eye testing platform with an initial focus on visual field testing for glaucoma.
This collaboration is a wonderful milestone for eye care in Switzerland, where glaucoma is one of the most common causes of blindness. Two out of every hundred people aged 40 and over suffer from glaucoma, 50,000 Swiss people are known to suffer from glaucoma caused by increased intraocular pressure, 10 percent of whom are at risk of blindness. However, the Swiss Ophthalmological Society (SOG) points out that the number of unreported cases in this area is very high. It is assumed that a total of around 100,000 people in Switzerland are affected by glaucoma. Therefore, innovative ways to diagnose and monitor the condition are needed to address this unmet clinical need.
Von Hoff and PeriVision will jointly exhibit at the Swiss Ophthalmology Congress (SOG) from August 28 – 30 in St. Gallen, Switzerland, and invite you to come by their booths to learn more about VisionOne and PeriVision’s clinical research. For more information about PeriVision, please visit www.perivision.com or contact info@perivision.com.
